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Key Messages
•  Lactose intolerance is often confused with cow’s milk 
allergy by patients and parents.
•  A better knowledge of the differences between these 
clinical conditions could limit misunderstandings in 
the diagnostic approach and management.
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Abstract
Lactose intolerance primarily refers to a syndrome having 
different symptoms upon the consumption of foods con-
taining lactose. It is one of the most common form of food 
intolerance and occurs when lactase activity is reduced in 
the brush border of the small bowel mucosa. Individuals may 
be lactose intolerant to varying degrees, depending on the 
severity of these symptoms. When lactose is not digested, it 
can be fermented by gut microbiota leading to symptoms of 
lactose intolerance that include abdominal pain, bloating, 
flatulence, and diarrhea with a considerable intraindividual 
and interindividual variability in the severity of clinical man-
ifestations. These gastrointestinal symptoms could be simi-
lar to cow’s milk allergy and could be wrongly labeled as 
symptoms of “milk allergy.” There are important differences 
between lactose intolerance and cow’s milk allergy; there-
fore, a better knowledge of these differences could limit mis-
understandings in the diagnostic approach and in the man-
agement of these conditions. © 2019 S. Karger AG, Basel
Introduction
The signs and symptoms of adverse food reactions 
(AFRs) in children derive from several mechanisms (see 
Fig. 1) [1]. These mechanisms can be triggered by differ-
ent components of the same food. Immune-mediated re-
actions (i.e., food allergy, celiac disease) are elicited by 
food proteins, whereas the vast majority of non-im-
mune-mediated AFRs derive from carbohydrate intoler-
ances (see Fig. 2). The most common carbohydrate intol-
erance in the pediatric age is lactose intolerance. During 
infancy, lactose accounts for most of the dietary carbo-
hydrates. Lactose is a disaccharide, which is present in 
many dairy products, composed by galactose linked to 
glucose via a β-1→4 glucosidic bond. Lactose is hydro-
lyzed by β-ga lactosidase (lactase) bound to the small in-
testine brush border membrane, then the monosaccha-
rides glucose and galactose are both actively absorbed in 
the small intestine. Lactose intolerance primarily refers 
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to a syndrome having different intestinal or extraintesti-
nal symptoms upon the consumption of foods contain-
ing lactose that derives from an insufficient level of lac-
tase activity in the brush border of the small bowel mu-
cosa [2]. 
Three Types of Lactose Intolerance
Different factors cause the lactase deficiency underly-
ing each type:
1. Congenital lactase deficiency (CLD): an extremely rare 
autosomal recessive disease characterized by absent or 
reduced enzymatic activity from birth.
2. Primary lactose intolerance or adult-type lactase defi-
ciency: a common autosomal recessive condition re-
sulting from a developmentally regulated change of 
the lactase gene expression.
3. Secondary lactase deficiency: a transient condition de-
riving from intestinal damage secondary to several dis-
eases such as infections, food allergy, celiac disease, 
small bowel bacterial overgrowth, Crohn’s disease, or 
radiation/chemotherapy-induced enteritis.
CLD is a rare (only a few cases have been described) 
and severe intestinal autosomal recessive disease, within 
the group of congenital diarrheal disorders, caused by 
the absence of lactase activity from birth (OMIM 223000) 
[3, 4]. This condition must be distinguished from the 
developmental lactose intolerance that could be ob-
served in premature infants. These subjects may have 
reduced levels of lactase because small intestinal lactase-
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Fig. 1. Classification of adverse food reactions.
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expressing enterocytes develop later in the third trimes-
ter. The main symptoms of CLD are watery diarrhea, 
intestinal meteorism, and malnutrition, beginning on 
the first days after birth with the onset of lactation with 
breast milk or lactose-containing formula. Symptoms 
disappear when patients change to a lactose-free diet. 
The typical feature of CLD is the absence or very low 
levels of lactase expression deriving from a mutation in 
lactase phlorizin hydrolase gene (LPH) located on 2q21.3 
[5, 6]. Most CLD cases have been described in Finland, 
where the disorder is enriched due to a founder effect 
and genetic drift [5, 7]. Premature stop codons and a 
truncated protein as a result of frame shifts, missense 
mutations in the coding region of LPH, or exon duplica-
tion are the most common genotypes identified in these 
patients [7–10]. Some other cases include mutations 
leading to single amino acid substitutions that can inter-
fere with the proper maturation and function of LPH [7, 
11]. More recently, severe forms of CLD elicited by mu-
tations in the LPH gene that occur in either a compound 
heterozygous or homozygous pattern of inheritance 
have been described [3]. 
In primary lactose intolerance, intestinal lactase ex-
pression falls off sharply, making dairy products diffi-
cult to digest later in childhood or adolescence. It is the 
most common type of lactose intolerance and it is ge-
netically determined. Approximately 70% of the global 
adult population are lactase non-persistent (hypolacta-
sia). The global distribution and the age at which lactase 
expression declines vary with ethnicity. In South Amer-
ica, Africa, and Asia, more than 50% are lactase non-
persistent. The condition is also common in Mediter-
ranean or Southern European populations. In some 
Asian countries, up to 100% are lactase non-persistent. 
In the United States, the percentage of lactase non-per-
sistence varies with ethnic origin with the lowest per-
centage in the population of European origin and the 
highest percentage in Hispanics and in the Afro-Amer-
ican population. People who develop primary lactose 
intolerance start life producing plenty of lactase, a ne-
cessity for infants, who get all their nutrition from milk. 
As children replace milk with other foods, their lactase 
production decreases. Children of African, Asian, or 
Hispanic descent may experience symptoms beginning 
between the age of 2 and 3 years, whereas subjects of 
European and American descent typically do not de-
velop symptoms of lactose intolerance until later in 
childhood (5–6 years of age) or adolescence [12–14]. 
Lactase persistence is inherited as a dominant Mende-
lian trait [15]. The genetic trait of persistence of intes-
tinal lactase expression can be caused by five or more 
independent single nucleotide variants in a regulatory 
region (a transcriptional enhancer) upstream of the 
lactase gene. One of these, −13910*T (rs4988235) is 
responsible for most cases of lactase persistence in 
Caucasian individuals, others such as −13907*G 
(rs41525747), −13915*G (rs41380347), −14009*G 
(rs869051967), and −14010*C (rs145946881) are found 
at variable frequencies in the Middle East and Africa 
[16, 17]. Several individual variables can influence the 
development of symptoms in non-persistence lactase 
subjects: dose of lactose in diet, intestinal transit time, 
lactase expression, distribution and fermentation abil-
ity of gut microbiota, sensitivity towards chemical and 
mechanical stimulation of the gut, and psychological 
factors [18–20]. Adaptation of gut microbiota, assum-
ing a growing dose of lactose, with increase of bacteri - 
al β-galactosidase activity is recognized as a cause of 
symptom reduction in lactose intolerance [21, 22]. 
Lastly, virtually all pathological conditions that cause 
small intestine damage can induce a reduction in lactase 
expression determining a secondary and transient lac-
tase deficiency. Among the diseases associated with sec-
ondary lactose intolerance there are celiac disease, small 
bacterial overgrowth, and Crohn’s disease. Treatment of 
the underlying disorder may restore lactase levels and 
improve signs and symptoms, though it can take time. 
Abdomen radiation therapy or chemotherapy could also 
lead to lactose intolerance. Cow’s milk allergy (CMA) 
can cause severe enteropathy with secondary lactase de-
ficiency. In these patients, there may be an overlap of 
gastrointestinal symptoms due to CMA and lactose in-
tolerance. Therefore, the same food, such as cow’s milk, 
can lead to an adverse reaction through different mecha-
nisms. 
Differences between Lactose Intolerance and CMA 
Frequently, among both patients and physicians, there 
is confusion between lactose intolerance and CMA, which 
could result in unnecessary dietary restriction or avoid-
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able reactions. “Milk allergy,” “milk intolerance,” and 
“lactose intolerance” are often used by patients and their 
parents without a clear sense of the different meanings, 
understanding of the different mechanisms that underlie 
them, or the dietary implications of the diagnosis. The 
management of these conditions is distinctly different, 
and inappropriate recognition or management may have 
significant implications for the patient [23].
Lactose intolerance results from a reduced ability to di-
gest lactose, a sugar. As explained above, lactose intoler-
ance is a “non-immune-mediated AFR,” while CMA is one 
of the most common forms of food allergy (“immune-me-
diated AFR”) in particular in the first years of life. CMA 
may be due to immunoglobulin E (IgE), non-IgE mediat-
ed, or mixed reactions. After food intake, IgE-mediated re-
actions typically occur within 2 h, whereas non-IgE-medi-
ated reactions develop after 2–48 h or some days after the 
food ingestion [24]. In particular, the symptoms of non-
IgE-mediated CMA are frequently wrongly labeled as 
symptoms of intolerance. The main differences between 
CMA and lactose intolerance are summarized in Table 1.
Clinical Symptoms of Lactose Intolerance 
Non-digested lactose in the intestinal tract drives flu-
ids into the gut lumen through an osmotic force, causing 
osmotic diarrhea. Moreover, gut microbiota fermented 
lactose, producing volatile fatty acids and gases (hydro-
gen, methane, and carbon dioxide). All these events are 
responsible for the clinical symptoms, such as distension 
of the small bowel, non-focal abdominal pain associated 
with bloating and flatulence, nausea, increased gut motil-
ity, and diarrhea [25]. These symptoms usually develop 
from 30 min to 2 h after the ingestion of lactose-contain-
ing foods. Food intolerances have long been reported by 
patients with functional gastrointestinal disorders; how-
ever, randomized controlled trials are lacking in this area 
[26]. Extraintestinal symptoms, such as headache, verti-
go, memory impairment, and lethargy, have been de-
scribed in up to 20% of subjects with carbohydrate intol-
erance [27]. These systemic symptoms could be the result 
of toxic metabolites, produced by sugar fermentation of 
colonic bacteria that can alter cell-signaling mechanisms 
[28]. However, it is unclear whether these atypical symp-
Table 1. Main differences between (adult-type) lactose intolerance and cow’s milk allergy
Lactose intolerance Cow’s milk allergy
Mechanism Enzyme deficiency Immune-mediated reaction
Onset of symptoms 5–6 years of age Peaks during the first year of life
Resolution Irreversible Tending to remit in childhood (2–5 years of age)
Food component involved Lactose, the primary digestible 
carbohydrate found in mammalian  
milk, including human milk
Cow’s milk proteins
Eliciting doses Grams From nanograms to milligrams 
Gastrointestinal symptoms Abdominal pain, nausea, bloating, 
flatulence and diarrhea (less  
common: constipation, vomiting)
IgE-mediated: urticaria, angioedema of the lips, tongue, and 
palate; oral pruritus; nausea; colicky abdominal pain; 
vomiting; diarrhea
Non-IgE-mediated: vomiting, diarrhea, blood and/or mucus 
in the stools, abdominal pain, malabsorption often 
associated with failure to thrive or poor weight gain
Extraintestinal symptoms Headache, vertigo, memory  
impairment and lethargy
IgE-mediated: skin (acute urticaria and/or angioedema); 
respiratory system (nasal itching, sneezing, rhinorrhea, or 
congestion, and/or conjunctivitis, cough, chest tightness, 
wheezing, or shortness of breath); other (signs or symptoms 
of anaphylaxis)
Non-IgE/IgE-mediated: atopic eczema
Test to confirm the diagnosis Lactose breath test Oral food challenge
Dietary treatment Low lactose diet Cow’s milk proteins-free diet
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toms are directly due to lactose ingestion or related to the 
presence of the so-called “functional disease,” frequently 
accompanied by multiple somatic complaints [17]. 
Diagnostic Approach to a Pediatric Patient with 
Suspected Lactose Intolerance
Genetic testing for mutations of the LPH gene should 
be performed whenever CLD is suspected in infants with 
typical symptoms and a positive response to dietary elim-
ination of lactose [29]. In secondary lactase deficiency, a 
good clinical history often reveals the relationship be-
tween lactose ingestion and symptoms. The mainstays of 
adult-type lactose intolerance diagnosis are anamnesis 
and the lactose breath test (LBT) [17]. The LBT is a rapid, 
non-invasive test that allows measuring the content of hy-
drogen in the expired air. The dose of lactose adminis-
tered is 1 g/kg in children. Although high doses of lactose 
(≥50 g) have been used for LBT, 25 g (equivalent of 500 
mL of milk) is within the normal range of consumption 
and is the recommended dose after 8–12 h of fasting [30]. 
All breath testing should incorporate measurement of 
CO2 (or O2) to adjust the breath sample for non-alveolar 
dilution of exhaled air [31]. Concomitant measurement 
of CH4 is also required because the detection rate of an 
early rise in H2 production significantly decreases in ex-
cess methane producers [30]. A cutoff increase of H2 of 
20 parts per million (ppm) above the baseline level is con-
sidered as positive (CH4 ≥10 ppm) (see Fig. 3).
Factors that may produce false-negative or false-posi-
tive results include conditions affecting the gut microbi-
ota (e.g., recent use of antimicrobial agents), lack of hy-
drogen-producing bacteria (10–15% of the population), 
ingestion of high-fiber diets before the test, small intesti-
nal bacterial overgrowth, or intestinal motility disorders 
[17, 32].
Another diagnostic test, quite popular in the past, is 
the lactose tolerance test. In this test, the patient suspect-
ed to have lactose intolerance assumes 50 g of lactose dis-
solved in water. Samples of capillary blood are taken to 
test the plasma glucose concentration at −5, 0, 15, 30, 45, 
and 60 min. A maximal plasma-glucose increase of 1.4 
mmol/L or higher indicates lactose tolerance [33]. The 
lactose tolerance test is not sensitive enough; it is also of-
ten falsely positive because of lack of an increase of blood 
glucose concentration attributable to a normal insulin re-
sponse to the carbohydrate load. Given the high rate of 
false-negative and false-positive results, this test should 
not be used and has been replaced by the LBT [34].
Pre-test conditions*:
• No antibiotics in the previous 4 weeks
• No prokinetics and laxatives in the previous 7 days
• No fermentable foods, such as complex carbohydrates,
 in the previous 24 h
• Physical activity should be limited during breath testing
Notes:
* It is not necessary to stop proton pump inhibitors and anti-acid medications prior to breath testing. A firm position statement
could not be reached due to lack of conclusive data on stopping or continuing probiotics or prebiotics prior to breath testing
(see [30]).
** Given the importance of CH4 in association with gastrointestinal symptoms and the interaction of CH4 with H2 production,
measurement of CH4 should be integrated in all breath tests.
Positive assessment:
• A rise of ≥20 ppm from baseline in H2 during the test
 should be considered positive
• Until further data is available, a level ≥10 ppm should
 be considered positive for CH4
Collect breath samples at 20-min intervals for
2–5 h and record symptoms
Fasting from solids
and liquids
–8 –12 h
Collect a breath sample
for determining H2 and
CH4 baseline value
–5 min
Start breast test
Lactose: 1 g/kg BW
(25 g mixed with or
followed by 1 cup of water)
0
Record H2 and CH4
levels and analyze
them**
2 h
Fig. 3. Lactose breath test procedure in children with suspected lactose intolerance.
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The genetic test, identifying single nucleotide poly-
morphism associated with lactase persistence/non-per-
sistence, is also available. It should be noted that the pres-
ence of the lactase non-persistent gene does not imply the 
simultaneous presence of lactose intolerance that may ap-
pear later in life. 
Management of Lactose Intolerance and Nutritional 
Issues
The mainstay of treatment for AFRs is to eliminate the 
causative food from the diet. In the AFRs induced by 
CMA, also small protein doses can cause symptoms, so 
the management is based on the strict avoidance of the 
cow’s milk-derived allergenic peptides in the diet. On the 
contrary, a reduction of lactose intake rather than full ex-
clusion is recommended in lactose intolerance, because 
available data suggest that adolescents and adults can 
usually ingest up to 12 g of lactose in a single dose (equiv-
alent to 1 cup of milk, corresponding to 240 mL) with no 
or minimal symptoms [35]. So, in these patients dietary 
treatment consists only in a low-lactose diet (Tables 2, 3) 
[2, 35]. There is no scientific evidence to identify the tol-
erable dose of lactose for children with lactose intoler-
ance. Determining the amounts of lactose that can be tol-
erated is necessary to develop evidence-based dietary rec-
ommendations that meet the needs of the individual. In 
primary lactose intolerance, lactose-containing dairy 
products are generally avoided for 2–4 weeks, the time 
required to induce symptom remission. Then, a gradual 
reintroduction of dairy products low in lactose up to a 
threshold dose of individual tolerance should be recom-
mended. 
In secondary hypolactasia, a restricted diet is necessary 
only for a limited time [35]. Concern about lactose intol-
erance and osmotic diarrhea in the treatment of under-
nourished children has led to a restricted use of lactose in 
these patients. Even in well-nourished children, low-lac-
tose formulas are frequently used in children with persis-
tent diarrhea. It is useful to find a balance where the 
amount of lactose in food does not induce osmotic diar-
rhea, but can help to achieve the  beneficial effects of lac-
tose. Clinical trials are needed to better define the safe and 
appropriate lactose dietary levels for moderately and se-
verely undernourished children [36]. In the rare form of 
CLD, a complete lactose-free diet is required for life. 
Enzyme replacement is another therapeutic approach in 
patients with lactose intolerance that wish to enjoy dairy 
products. Preliminary data showed an improvement of gas-
trointestinal symptoms and a decrease of H2 levels at breath 
test with the administration of 1,500 U/day of β-galactosidase. 
However, more data regarding the efficacy of this micro-
Table 2. Lactose content in common dairy foods
Food Lactose, g/100 g of food
Skimmed cow’s milk 
Low-fat cow’s milk 
Whole cow’s milk 
Buttermilk 
Lactose-free milk 
Whole powdered milk 
Skimmed powdered milk 
Goat’s milk 
Buffalo milk 
Yogurt 
Butter 
Cottage cheese 
Mozzarella cheese 
Goat cheese 
Ricotta cheese 
Parmigiano Reggiano cheese 
Cream cheese 
Taleggio cheese 
Fontina cheese 
Provolone cheese 
Gorgonzola cheese 
4.7
4.6
4.5
4.1
0.5
35.1
50.5
4.2
4.9
3.2
4.0
2.6
1.5–2.0
1.5–2.0
4.0
0–0.9
6.0
0
0
0
0
Table 3. Low-lactose diet
Food to limit
– 
– 
– 
– 
– 
All kinds of milk: whole, low fat, non-fat, cream, powdered, 
condensed, evaporated, goat, acidophilus, and chocolate
Butter, cottage cheese, ice cream, creamy/cheesy sauces, 
cream cheeses, soft cheeses (brie, ricotta), mozzarella, 
whipped cream, yogurt
Fish and meat (breaded or creamed)
Milk bread, crackers, creamed, scalloped, or au gratin 
potatoes
Muffin, biscuit, waffle, pancake, and cake mixes; milk 
chocolate; bakery products and desserts that contain the 
ingredients listed above
Foods allowed
– 
– 
– 
– 
– 
– 
– 
– 
Lactose-free milk, soy milk
Lactose-free dairy, hard cheeses (Parmigiano Reggiano, 
Pecorino, Grana Padano, fontina, taleggio, provolone,
Swiss), gorgonzola
All fruits
All vegetables
All legumes
All cereals
All meat, fish, and eggs
All vegetable fats
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bial exogenous enzyme are needed [37]. Other evidence 
suggested that efficacy of exogenous lactase was obtained 
from Kluyveromyces lactis, Aspergillus oryzae, or Kluyvero-
myces lactis [38, 39]. Another strategy involves probiotics 
that could shape gut microbiota composition. Four-week 
consumption of a mix probiotic combination (Lactobacil-
lus casei Shirota and Bifidobacterium breve) improved 
symptoms and decreased H2 production in lactose-intoler-
ant patients. These effects appeared to be persistent for at 
least 3 months after suspension of probiotic consumption 
[40], and strain-specific because in a similar study a milk 
containing L. acidophilus resulted ineffective [41]. A ran-
domized, double-blind, placebo-controlled trial conducted 
in adult lactose-intolerant patients demonstrated that a 36-
day treatment with a highly purified (> 95%) short-chain 
galactooligosaccharide (GOS), designated “RP-G28” (esca-
lating doses from 1.5 to 15 g/day) plus subsequent dairy 
consumption significantly improved clinical outcomes for 
lactose digestion and tolerance. These clinical outcomes 
correlated with a significant modification in gut microbiota 
composition consisting of an increase in lactose-ferment-
ing Bifidobacterium, Faecalibacterium, Lactobacillus, and 
Roseburia [42]. Further studies are required to provide 
high-quality evidence to support or compare the efficacy of 
all these strategies.
In the management of lactose-intolerant patients, it is 
important to consider that lactose intolerance can be part 
of a wider intolerance to variably absorbed, fermentable 
oligo-, di-, monosaccharides and polyols (FODMAPs). 
This is present in a high percentage of patients with irri-
table bowel syndrome and this group requires not only 
restriction of lactose intake but also a low-FODMAP diet 
to improve gastrointestinal symptoms [17]. 
“Free” diets are in fashion. In supermarkets tons of 
products labeled lactose-free can be easily found; there 
are more and more cafes, ice-cream shops, bakeries, 
and restaurants offering special menus, where lactose 
has been banished. Milk consumption is decreasing in 
the USA and is the lowest in countries with a high prev-
alence of lactase non-persistence [14]. Indeed, the Na-
tional Health and Nutrition Examination Survey 
(NHANES) reported approximately 5% of infants re-
ceived lactose-reduced formulas in the USA alone be-
tween 2003 and 2010, and this trend is increasing [43]. 
A common rationale for the use of lactose-free infant 
formulas is that infants are presumed to be lactose in-
tolerant; although there is little or no evidence that lac-
tose-reduced formulas are beneficial [44]. Preliminary 
evidence shows that elimination of lactose from the in-
fants’ diet is disadvantageous for the development of 
healthy gut microbiome [45] and a different plasma 
metabolic profile in lactose-free formula-fed children 
[46]. A lactose-free diet should be prescribed only when 
a true diagnosis of lactose tolerance is achieved. A full 
dairy exclusion diet may also affect other health out-
comes. It is important to underline that if dairy prod-
ucts are eliminated, other dietary sources of calcium or 
calcium supplements need to be provided. The current 
recommendations for calcium intake are 700 mg/day 
for children aged 4–9 years, and 1,300 mg/day over 10 
years, according to the EFSA guidelines [47]. Educa-
tional and commercial efforts to improve calcium and 
vitamin D intake are now focusing on stimulating the 
consumption of tolerable amounts of milk, use of low-
ered lactose-containing foods including hard cheeses, 
yogurt, and lactose-hydrolyzed milk products.
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